Mergetpa 是一种具有高亲和力的可逆 Arg-carboxypeptidase 抑制剂,可降低 B1R,阻断葡萄糖喂饲大鼠中 IL-1β 蛋白及 mRNA 的过表达,同时显著增加肾皮质中 IL-1β 蛋白的表达,并用于阻断激肽和 B2 受体拮抗剂转化为缺乏 c 端精氨酸的代谢物,还可抑制离体兔主动脉对缓激肽的反应随时间增强、保留全长 SDF-1α 对细胞的趋化活性,以及逆转葡萄糖喂养大鼠的高血糖、过度体重增加、氧化应激标志物水平升高及炎症标志物过表达。
产品编号: MS-T84194 纯度: 95.55% CAS No.: 77102-28-4 分子式: C7H15N3O2S2 分子量: 237.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Mergetpa 是一种具有高亲和力的可逆 Arg-carboxypeptidase 抑制剂,可降低 B1R,阻断葡萄糖喂饲大鼠中 IL-1β 蛋白及 mRNA 的过表达,同时显著增加肾皮质中 IL-1β 蛋白的表达,并用于阻断激肽和 B2 受体拮抗剂转化为缺乏 c 端精氨酸的代谢物,还可抑制离体兔主动脉对缓激肽的反应随时间增强、保留全长 SDF-1α 对细胞的趋化活性,以及逆转葡萄糖喂养大鼠的高血糖、过度体重增加、氧化应激标志物水平升高及炎症标志物过表达。

生物实验数据

生物活性 Mergetpa is a high-affinity reversible Arg-carboxypeptidase inhibitor that reduces B1R, blocks IL-1β protein and mRNA overexpression in glucose-fed rats while significantly increasing IL-1β protein expression in the renal cortex, and is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking C-terminal arginine; it also inhibits the time-dependent enhancement of bradykinin responses in isolated rabbit aorta, preserves the chemotactic activity of full-length SDF-1α toward cells, and reverses hyperglycemia, excessive weight gain, elevated oxidative stress marker levels, and inflammatory marker overexpression in glucose-fed rats.
IC50 & Target

IL-1β

 

Bradykinin B1 Receptor (B1R)

 

体外研究
(In Vitro)

Mergetpa (8.43×10-6 M; 1-6 h) 在离体兔主动脉中可抑制缓激肽诱导的收缩随时间增强的效应。
Mergetpa (8.42×10-6 M) 在离体兔颈静脉中不会改变 B2 受体拮抗剂的表观亲和力。
Mergetpa (5 μM; 10 min) 可保留 SDF-1α (1-68) 对骨髓和脐带血 CD34+ 细胞的趋化活性。
Mergetpa (5 μM; 30 min) 可使 THP-1 细胞对全长 SDF-1α (1-68) 的趋化反应提高 1.4 倍,但对细胞向截短型 des-lys SDF-1α (1-67) 的迁移无影响。

体内研究
(In Vivo)

Mergetpa (1 mg/kg;皮下注射;每日 2 次;连续 7 天) 可使胰岛素抵抗的高糖喂养大鼠的高血糖恢复正常、逆转体重增加、使氧化应激标志物恢复至对照组水平,并阻断炎症及 B1R 通路标志物的高表达,但对高瘦素血症或高血压无影响。

Animal Model: Sprague-Dawley (male, 24-30 days old, 50-75 g at study initiation, insulin resistance induced via 9 weeks of ad libitum 10% D-glucose drinking solution)
Dosage: 1 mg/kg
Administration: s.c.; twice daily; 7 days
Result: Normalized two-fold elevated blood glucose levels in glucose-fed rats to values not significantly different from control rats.
Halved four-fold elevated plasma insulin levels in glucose-fed rats (reduction did not reach statistical significance).
Markedly reduced (P < 0.05) elevated HOMA index of insulin resistance in glucose-fed rats, though not to full control levels.
Induced significant body weight loss (18 g, P < 0.05) in glucose-fed rats, reversing their previously increased body weight gain, but did not affect body weight gain in control rats.
Did not alter elevated plasma leptin levels or systolic blood pressure in glucose-fed rats.
Normalized elevated basal superoxide anion production in the aorta of glucose-fed rats to control levels.
Significantly reduced (P < 0.05) enhanced nitrotyrosine expression in the renal cortex and aorta of glucose-fed rats to levels not significantly different from control rats.
Restored significantly enhanced B1R protein and mRNA expression in the renal cortex, thoracic aorta, and liver of glucose-fed rats to control levels.
Completely blocked (P < 0.05) enhanced CPM protein expression in the renal cortex, thoracic aorta, and liver of glucose-fed rats.
Abolished significantly enhanced iNOS protein expression in the renal cortex, thoracic aorta, and liver of glucose-fed rats.
Fully blocked (P < 0.05) enhanced IL-1β protein and mRNA expression in the renal cortex, thoracic aorta, and liver of glucose-fed rats.
Did not significantly affect blood glucose, plasma insulin, HOMA index, superoxide anion production, B1R expression, CPM expression, or iNOS expression in control rats; significantly reduced nitrotyrosine expression in control aorta (but not renal cortex) and increased IL-1β protein expression in control renal cortex.
性状 固体
颜色 White to off-white

化学信息

分子量 237.34
分子式 C7H15N3O2S2
CAS No. 77102-28-4

储存&溶解度

储存方式

4°C, stored under nitrogen, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 15 mg/mL (63.20 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM4.2134 mL21.0668 mL42.1336 mL105.3341 mL
5 mM0.8427 mL4.2134 mL8.4267 mL21.0668 mL
10 mM0.4213 mL2.1067 mL4.2134 mL10.5334 mL
15 mM0.2809 mL1.4045 mL2.8089 mL7.0223 mL
20 mM0.2107 mL1.0533 mL2.1067 mL5.2667 mL
25 mM0.1685 mL0.8427 mL1.6853 mL4.2134 mL
30 mM0.1404 mL0.7022 mL1.4045 mL3.5111 mL
40 mM0.1053 mL0.5267 mL1.0533 mL2.6334 mL
50 mM0.0843 mL0.4213 mL0.8427 mL2.1067 mL
60 mM0.0702 mL0.3511 mL0.7022 mL1.7556 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础